Bormioli Pharma, an international leader in the production of pharmaceutical packaging and medical devices, today announced robust growth in its North American business in 2022, with sales increasing more than 40% year-over-year. The growth in North America was matched by strong sales gains in the company’s markets worldwide, with an annual turnover of 315 million euros, reflecting the company’s multimillion dollar investments in expanding its capabilities as a provider of comprehensive packaging solutions for injectable drugs.
The U.S. glass bottle market is dealing with continuing supply issues for injectable glass packaging as a result of lingering effects of the COVID-19 pandemic and resulting supply chain disruptions. Bormioli Pharma is committed to providing a comprehensive solution with its ever-expanding capabilities in the area of high-value glass vials, rubber stoppers and aluminum seals. Specifically, the company has invested in strengthening its tubular glass vials capabilities through advanced machinery, while upgrading its platform for molded glass, and expanding clean-room capabilities for the production of rubber stoppers. These developments were supported by recent acquisitions that enable the company to reliably and efficiently produce rubber and aluminum closures, as well as tubular glass vials.
“For almost 200 years, we have been leading the field of molded glass manufacturing and now we have expanded those capabilities to tubular glass vials designed for injectable drugs and vaccines,” noted Andrea Lodetti, CEO of Bormioli Pharma. “Our proud history is matched by our current passion for innovation in the provision of innovative comprehensive packaging solutions for drug makers. As a single supplier of all the components of the injection drug kit, we can offer a wide variety of cost-effective, flexible solutions tailored to the customer’s needs, while also pursuing an ambitious agenda to greatly increase the sustainability of all our operations. Our multi-faceted commitments are driven by two major factors – the supply chain issues from the continuing shortage of glass packaging for injectable drugs and the stark reminders of the inescapable dangers of ongoing climate change”.
These solutions will be presented to the North American market at DCAT Week in New York from 20th to 23rd March. DCAT Week 2023 will also be the occasion to showcase the ESG targets the company has set in terms of environmental and social sustainability.
Among these, the use the 50% of sustainable raw materials in production by 2025, a goal to which the company is closer year after year. Latest achievements will be reported in the 2022 ESG Report of Bormioli Pharma, that will be published in a few weeks.
Bormioli Pharma commitment to sustainability is also demonstrated by the launch of EcoPositive, a new range of eco-friendly solutions, developed consistently with 3 different sustainability approaches:
- Regenerate: glass and plastic packaging recycled from first-choice waste collection
- Renew: bioplastic packaging derived from renewable sources
- Reloop: glass and advanced polymer products made from infinitely reusable
materials
These glass and plastic solutions can be provided together with detailed LCA studies, as well as with extractables testing showing the safety in any conditions of these solutions in respect to conventional ones.
